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Abstract: The paradoxical adverse effects of tumor necrosis factor-alpha (TNF-alpha) antagonists have been described frequent-
ly as a result of the widespread use of these drugs. Among the TNF-alpha blocking agents, few reports exist relating the use of
adalimumab in cutaneous sarcoidosis, although all of them show good results. More recently, sarcoidosis onsets have been
reported with various TNF-alpha inhibitors. The current case is, to our knowledge, the first to describe the exacerbation of cuta-
neous lesions of sarcoidosis treated with adalimumab.
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Resumo: Os efeitos paradoxais dos anti-TNF-alpha têm sido cada vez mais descritos com a utilização mais ampla dessas dro-
gas. Entre os TNF-alpha, registam-se poucos casos com a utilização de adalimumab no tratamento da sarcoidose cutânea, sendo
que todos eles apresentam bons resultados. Têm sido descritos, mais recentemente, casos de sarcoidose induzidos por vários
anti-TNF-alpha. O presente caso é, até à data, o primeiro a descrever a exacerbação de lesões cutâneas de sarcoidose tratadas
com adalimumab.
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INTRODUCTION
Sarcoidosis is a multisystemic inflammatory
disorder of unknown cause1,2 and for which there is no
universally accepted treatment. Systemic agents such
as corticosteroids are often effective, and steroid-spar-
ing agents such as methotrexate, azathioprine, anti-
malarial drugs, pentoxifylline, allopurinol and
thalidomide have been shown to be beneficial for
selected patients, but their use is limited due to signif-
icant toxic effects of their own and inconsistencies in
efficacy.1 Refractory systemic and cutaneous sarcoido-
sis has been shown to improve with inhibition of TNF-
α. Few reports are available with adalimumab in the
treatment of cutaneous sarcoidosis. With the wide-
spread use of TNF-α antagonists, paradoxical adverse
effects have been described more frequently with
these drugs and are defined as the onset or exacerba-
tion of disorders that are usually improved by their
administration.2,3 Psoriasis onset or exacerbation and
sarcoid-like-granulomatosis onset has been more fre-
quently reported with TNF-α inhibitors, but rare cases
of exacerbation of cutaneous sarcoidosis have been
documented with them.3,4
The authors describe a clinical case of cuta-
neous sarcoidosis in which the treatment with adali-
mumab was not only ineffective, but exacerbation of
the disease was observed.
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CASE REPORT
A 50-year-old female was observed due to ery-
thematous, infiltrated, sometimes ulcerated plaques,
on the frontal and left preauricular areas lasting for 2
years. (Figure 1). The patient had high blood pressure
and was treated with bisoprolol 5mg/day.
The plaque on the left preauricular area was
biopsied. Biopsy was performed showing dermal
granuloma, without central caseous necrosis and
numerous Langhans multinucleated giant cells.
(Figure 2) Acid-fast bacteria stains were negative as
well as tissue cultures for mycobacteria, bacteria and
fungi. Infectious etiology was excluded and the diag-
nosis of cutaneous sarcoidosis was made. Except for
cutaneous involvement, the patient was in good
health with no systemic symptoms. Further evalua-
tions included a complete blood cell count and com-
plete metabolic panel, both of which revealed no sig-
nificant abnormal findings. C-reactive-protein,
angiotensin-converting-enzyme (ACE) and calcium
were in the normal range. Further investigation for
systemic involvement was negative. Local therapy
with topical and intralesional corticosteroids
(momethasone furoate and clobetasol propionate
creams; betamethasone dipropionate and betametha-
sone phosphate sodium aqueous suspension, succes-
sively) and topical tacrolimus failed.
Hydroxychloroquine sulfate (400 mg daily), pentoxi-
fylline (400 mg daily), methylprednisolone (up to 25
mg daily), azathioprine (100 mg daily) and methotrex-
ate (up to 27,5 mg /week until cumulative dosis of 733
mg) produced no significant effect.
Long-term treatment with systemic corticos-
teroids, azathioprine or methotrexate was felt to be
unwarranted because of the risk of serious long-term
sequelae. Treatment with adalimumab was proposed
as an alternative to treatment with methotrexate.
Tuberculin skin test was performed before initi-
ating the biological agent and revealed a 1.1 millimeter
papule. Therefore isoniazid (300mg/day) was started.
Methotrexate was gradually tapered to 7.5
mg/week and methylprednisolone (4 mg/day) and
then stopped. Adalimumab (40 mg subcutaneously at
week 1, 3 and 5) was started two months after the start
of isoniazid. Adalimumab was then suspended (after
the third injection) because the lesions became more
erythematous, infiltrated, ulcerated and associated to
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FIGURE 1: (A) Plaque of sarcoidosis on the
frontal area and (B) on the left preauricular
area just before adalimumab; (C) Plaque on
the frontal area and (D) on the left preauricu-
lar area after 3 injections of adalimumab
FIGURE 2: Histopathology H&Ex200. Sarcoid granuloma in the reti-
cular dermis (with epithelioid hystiocytes, Langhans giant cells,
without necrosis and some peripheral lymphocytes)
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retroauricular adenopathies (Figure 1). Shortly after
suspension, the lesions improved.
DISCUSSION
Effective management of patients with sar-
coidosis remains problematic. Recent clinical trials of
TNF-α inhibitors for the treatment of sarcoidosis have
reported mixed results.2 Anti-TNF-α blockers appear
to be effective in the manifestations of refractory sar-
coidosis but they are not approved by the FDA for the
treatment of sarcoidosis. A survey of the available lit-
erature revealed only 6 articles which report treatment
of cutaneous sarcoidosis with adalimumab and all
these reports revealed good results.5-10 These reports
showed adalimumab efficacy in different clinical set-
tings, including leg ulcer, cutaneous nodules and
plaques on the face and lupus pernio. Three patients
were treated previously with another anti-TNF-α (1
etanercept and 2 infliximab).5,6,7 Switching to another
blocker resulted in clinical improvement, which indi-
cates that the granulomatosis occurrence is not pre-
dictable. The pathogenesis of worsening of sarcoidosis
as the induction of sarcoid-like granuloma under
these blockers is still not well understood. Disease
heterogeneity and differences in pharmacokinetics,
pharmacodynamics and mechanisms of action may
account for these effects.
A growing number of reports concerning para-
doxical adverse events due to TNF-alpha antagonists
have been published.2,4 Most of the information avail-
able comes from isolated clinics cases or small series
of cases.
There are more than 42 paradoxical effects of
sarcoidoid-like granuloma during anti-TNF-α thera-
py.3 Non-exclusively cutaneous involvement was
more frequent. The suggested role of TNF-alpha in the
genesis of granulomas has led researchers to investi-
gate anti-TNF-alpha treatment of granuloma forma-
tion diseases.
Genetic variations of the TNF-α gene is emerg-
ing as an important factor in determining sarcoidosis
predisposition and course. Polymorphism of the
genes that mediate cytokine production may be asso-
ciated with distinct immune pathways, but implica-
tions of TNF-alpha genes and the predisposition to
resistance to therapy are still not known.
Only a fraction of the treated population nor-
mally responds to biologics, and clinical markers for
the prediction of the efficacy are seldom available.2
In our case, although methylprednisolone was
stopped and methotrexate slightly tapered, this sug-
gests a possible triggering role of the anti-TNF-α ther-
apy because of the prompt clinical improvement after
discontinuation of adalimumab.
Paradoxical effects of TNF-alpha blockers in
sarcoidosis are based on the supposed efficacy of
these agents in this disease.2 The worsening of the
patient´s lesions with adalimumab contributes to the
reports of paradoxical adverse events during TNF-α
blocking agents.
To our knowledge, our case is the first paradox-
ical exacerbation with adalimumab and the third case
to describe worsening of pre-existing cutaneous sar-
coidosis with an anti-TNF-alpha antagonist. A better
understanding of the pathogenic role of TNF-α in sar-
coidosis and of its therapeutic blocking action will
help to explain this phenomenon. The development of
pharmacogenomics to identify responders or non-
responders is highly desirable.2 q
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